Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.53
-0.0900-2.49%
Post-market: 3.530.00000.00%19:30 EDT
Volume:1.04M
Turnover:3.64M
Market Cap:110.45M
PE:-0.85
High:3.61
Open:3.58
Low:3.35
Close:3.62
52wk High:49.25
52wk Low:3.35
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.35
T/O Rate:5.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.50
PE(LYR):-1.24

Loading ...

Tempest Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 25

Arcturus Therapeutics Raised to Buy from Neutral by Citigroup

Dow Jones
·
Sep 24

Tempest Therapeutics price target lowered to $7 from $11 at H.C. Wainwright

TIPRANKS
·
Sep 24

Oruka Therapeutics Price Target Maintained with a $165.00/Share by Wedbush

Dow Jones
·
Sep 24

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

GlobeNewswire
·
Sep 24

Turn Therapeutics Initiated at Buy by LUCID Capital Markets

Dow Jones
·
Sep 24

Press Release: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for up to $47 Million

Dow Jones
·
Sep 24

Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8

MT Newswires Live
·
Sep 24

Arcturus Therapeutics upgraded to Buy from Neutral at Citi

TIPRANKS
·
Sep 24

Chordia Therapeutics Completes Initial Expansion Cohort Enrollment for Rogocekib Trial

TIPRANKS
·
Sep 24

GenFleet Therapeutics Announces Resignation of Non-Executive Director

TIPRANKS
·
Sep 24

Ceryvyn Therapeutics Issues 3 Million Unquoted Long-Dated Options

TIPRANKS
·
Sep 24

Press Release: Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

Dow Jones
·
Sep 24

Decoy Therapeutics Inducement Warrants Boost Near-Term Liquidity

TIPRANKS
·
Sep 24

Stoke Therapeutics names Bo Cumbo to board of directors

TIPRANKS
·
Sep 24

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

GlobeNewswire
·
Sep 24

Autolus Therapeutics management to meet virtually with William Blair

TIPRANKS
·
Sep 24

Maze Therapeutics Price Target Maintained with a $48.00/Share by Wedbush

Dow Jones
·
Sep 23

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

MT Newswires Live
·
Sep 23

Travere Therapeutics receives notice of allowance for FILSPARI patent

TIPRANKS
·
Sep 23